Tumour-on-Chip Models for Ovarian Cancer Research Show Promise and Challenges

Ovarian cancer, a highly lethal malignancy, is often diagnosed at late stages and develops chemoresistance, making treatment a significant challenge. Existing preclinical models have limitations in recapitulating the structural and functional complexity of the ovarian tumour microenvironment. However, a new study from Imperial College London suggests that tumour-on-chip (CoC) technology has the potential to revolutionize ovarian cancer research by enabling the co-culture of tumour and stromal cells within a microengineered platform.

Key Takeaways:

• The ovarian tumour microenvironment (TME) is complex and challenging to model in preclinical studies, with existing models only partially recapitulating its structural and functional characteristics.
• Tumour-on-chip (CoC) technology has emerged as a promising alternative for ovarian cancer research, enabling the co-culture of tumour and stromal cells within a microengineered platform that incorporates relevant extracellular matrix components and biochemical gradients.
• The study analyzed published ovarian cancer-specific CoC models and found a surprisingly limited number of studies and a lack of standardization across design parameters, materials, and outcome measures.
• The researchers identified critical technical and biological considerations for designing next-generation CoC platforms, aiming to improve their reproducibility, translational value, and potential for personalized medicine applications.
• Sung Yeon Lim and Mona El-Bahrawy, in collaboration with Lamia Sabry Aboelnasr, conducted the research at Imperial College London.
• The study highlights the importance of standardization and reproducibility in CoC models for ovarian cancer research.

Statistics:

• Ovarian cancer is a highly lethal malignancy, with a 5-year survival rate of 45% (Cancer Statistics 2025).
• The ovarian tumour microenvironment is complex, with inter- and intra-tumoural heterogeneity and frequent chemoresistance ( Tumour-on-Chip Models for the Study of Ovarian Cancer: Current Challenges and Future Prospects).
• Only 10% of ovarian cancer patients are diagnosed at an early stage, with 70% of cases diagnosed at stage III or IV (Cancer Statistics 2025).

Sources:

• Tumour-on-Chip Models for the Study of Ovarian Cancer: Current Challenges and Future Prospects. Cancers, 2025;17(19):3239.
• Cancer Statistics 2025.
• NewsRx. Findings from Imperial College London in Ovarian Cancer Reported (Tumour-on-Chip Models for the Study of Ovarian Cancer: Current Challenges and Future Prospects). OBGYN & Reproduction Week. October 27, 2025; p 183.